Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    AGN

SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

ALLERGAN PLC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/26/2017 | 11:04pm CEST

Item 1.01. Entry into a Material Definitive Agreement.


On May 26, 2017, Allergan Funding SCS (formerly known as Actavis Funding SCS), a
limited partnership (société en commandite simple) organized under the laws of
the Grand Duchy of Luxembourg ("Allergan SCS") and an indirect wholly-owned
subsidiary of Allergan plc (the "Company"), closed its previously announced
public offering of €2.7 billion aggregrate principal amount of notes
(collectively, the "Securities"). The Securities were issued pursuant to an
indenture dated as of March 12, 2015 (the "Base Indenture"), as supplemented by
the third supplemental indenture, dated as of May 26, 2017 (the "Third
Supplemental and, together with the Base Indenture, the "Indenture") among
(i) Allergan SCS, (ii) Warner Chilcott Limited, a Bermuda exempted company,
(iii) Allergan Capital S.à r.l. (formerly known as Actavis Capital S.à r.l.), a
private limited liability company (société à responsabilité limitée)
incorporated under the laws of the Grand Duchy of Luxembourg, and (iv) Allergan
Finance, LLC (formerly known as Actavis, Inc.), a Nevada limited liability
company, all indirect wholly-owned subsidiaries of Allergan plc (collectively,
the "Guarantors"), as guarantors.

The Securities and the guarantees are unsecured and unsubordinated obligations
of Allergan SCS and the Guarantors, which rank equally in right of payment with
all existing and future unsecured and unsubordinated indebtedness of Allergan
SCS and the Guarantors and senior in right of payment to all existing and future
subordinated indebtedness of Allergan SCS and the Guarantors. The Securities
will be structurally subordinated to all existing and future indebtedness and
other liabilities and commitments of subsidiaries of Allergan SCS and of the
Guarantors that do not guarantee the Securities. Certain terms of the Securities
are as follows:



Description                            Princial Amount                Maturity               Price to Public
0.500% Notes                          €      750,000,000                June 1, 2021                   99.537 %
1.250% Notes                          €      700,000,000                June 1, 2024                   99.355 %
2.125% Notes                          €      550,000,000                June 1, 2029                   99.465 %
Floating Rate Notes*                  €      700,000,000                June 1, 2019                  100.102 %

* The Floating Rate Senior Notes due 2019 will bear interest at a floating rate equal to three-

month EURIBOR plus 0.350% per annum.

The Indenture does not contain any financial covenants or provisions limiting Allergan SCS or the Guarantors from incurring additional indebtedness. The Indenture limits the ability of Warner Chilcott Limited and certain of its subsidiaries to incur liens, enter into sale and leaseback transactions and engage in certain business activities, in each case subject to certain qualifications set forth in the Indenture.

In the event of a Change of Control Triggering Event (as defined in the Indenture), each holder of the Securities will have the right to require Allergan SCS to purchase all or a portion of such holder's Securities at a purchase price equal to 101% of the aggregate principal amount of such Securities, plus accrued and unpaid interest to but excluding the date of such purchase.


The Securities will mature on the dates set forth in the Indenture. However,
Allergan SCS, at its option, may redeem any or all of the series of fixed rate
notes, in each case, in whole or in part, at any time or from time to time, at
the applicable redemption prices described in the Indenture.

The above description of the Indenture does not purport to be a complete statement of the parties' rights and obligations under the Indenture and is qualified in its entirety by reference to the terms of the Base Indenture and the Third Supplemental Indenture attached hereto as Exhibit 4.1.

Item 8.01. Other Events.

On May 26, 2017 the Company issued a press release announcing the closing of the offering of the Securities by Allergan SCS.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

--------------------------------------------------------------------------------

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits



Exhibit                                Description of Exhibit

Exhibit 4.1*     Third Supplemental Indenture dated May 26, 2017, among Allergan
                 Funding SCS and Warner Chilcott Limited, Allergan Capital S.à r.l.
                 and Allergan Finance, LLC, as guarantors, and Wells Fargo Bank,
                 National Association, as trustee.

Exhibit 5.1*     Opinion of Cleary Gottlieb Steen & Hamilton LLP.

Exhibit 5.2*     Opinion of Loyens & Loeff Luxembourg S.à r.l.

Exhibit 5.3*     Opinion of Appelby (Bermuda) Limited.

Exhibit 5.4*     Opinion of Greenberg Traurig LLP.

Exhibit 23.1     Consent of Cleary Gottlieb Steen & Hamilton LLP (contained in
                 Exhibit 5.1 above).

Exhibit 23.2     Consent of Loyens & Loeff Luxembourg S.à r.l (contained in Exhibit
                 5.2 above).

Exhibit 23.3     Consent of Appleby (Bermuda) Limited (contained in Exhibit 5.3
                 above).

Exhibit 23.4     Consent of Greenberg Traurig LLP (contained in Exhibit 5.4 above).

Exhibit 99.1*    Press Release of Allergan plc entitled "Allergan Announces Closing
                 of Public Offering of Senior Notes to Refinance Existing Debt"
                 dated May 26, 2017.




* Exhibits filed herewith


--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN, INC.
05/26 ALLERGAN PLC : Entry into a Material Definitive Agreement, Other Events, Financi..
05/25 ALLERGAN PLC : Other Events, Financial Statements and Exhibits (form 8-K)
05/24 ALLERGAN : Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch R..
05/23 ALLERGAN PLC : Other Events, Financial Statements and Exhibits (form 8-K)
05/18 HEALTH CANADA APPROVES ALLERGAN PLC : AGN) IBS Drug Viberzi
05/16 ALLERGAN : Eyepowerment™ Campaign Releases Survey Revealing the Importance..
05/16 ALLERGAN : VIBERZI™ Now Approved in Canada for patients with irritable bow..
05/16 CARL ICAHN : Icahn takes new 19.8 million share stake in Conduent in first quart..
05/13 High-profile Snap stakeholders revealed in filings
05/13 High-profile Snap stakeholders revealed in filings
More news
Sector news : Pharmaceuticals - NEC
06:49p WARREN BUFFETT : Warren Buffett takes 3 percent stake in Germany's Lanxess
06:41pDJMERCK : Congo Approves Anti-Ebola Vaccine to Combat Outbreak in Remote Northeast
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 MANNKIND : A Head Pain Gain Or A Pocket-Book Drain?
2015 Tracking Dan Loeb's Third Point Portfolio - Q1 2015 Update
2015 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2015 Update
2015 Time Warner Is A Buy - Cramer's Lightning Round (5/21/15)
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
Ambrose Robert Douglas Bailey Chief Executive Officer
Maria Teresa Hilado Chief Financial Officer
Raymond H. Diradoorian Executive VP-Global Technical Operations
Joann Bradley Investor Relations Contact
David Nakasone Investor Relations Contact
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN, INC.13.00%0
JOHNSON & JOHNSON10.16%341 901
ROCHE HOLDING LTD.14.62%236 581
NOVARTIS AG6.07%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results